Besides, the anti-BCMA/CD3 BiTE AMG-420, formerly known as BI 836909, has shown promising activity in r/r MM, including MRD-negative complete responses (NCT02514239) [149], with an ongoing expansion study (NCT03836053), while the anti-CD33/CD3 BiTE AMG-330 is currently in phase 1 testing (NCT02520427) [150]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.